Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data

This article was originally published in The Tan Sheet

Executive Summary

A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks

You may also be interested in...



Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda

The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.

Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda

The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.

FDA Targets Acetaminophen Safety Evaluation In Plan To Mine OTC Use Data

An RFP to provide FDA with direct access to data on consumers’ OTC use identifies the public health impact of potential changes in dosing information on acetaminophen product labels as one reason for the planned data evaluation. Access to the data also will increase FDA’s ability to perform regulatory impact studies, particularly to assess the impact of Rx-to-OTC switches.

Related Content

Topics

UsernamePublicRestriction

Register

PS103090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel